Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date

S Si, DT Teachey - Therapeutics and clinical risk management, 2020 - Taylor & Francis
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …
被引用次数：96 相关文章
[HTML] nih.gov

[HTML][HTML] Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and Clinical Risk Management, 2020 - ncbi.nlm.nih.gov
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and clinical risk …, 2020 - pubmed.ncbi.nlm.nih.gov
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.

S Si, DT Teachey - Therapeutics and Clinical Risk Management, 2020 - europepmc.org
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and Clinical Risk …, 2020 - search.proquest.com
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and Clinical Risk Management, 2020 - dovepress.com
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and Clinical Risk Management, 2020 - dovepress.com
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

S Si, DT Teachey - Therapeutics and clinical risk …, 2020 - pubmed.ncbi.nlm.nih.gov
Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have
revolutionized the landscape of cancer treatment in recent years. Although this class of …